Raouf Mina Maher, Salem Gehan Ibrahim Abdelrazek, Malek Fady Adib Abdel, Hamawy Tamer Youssef Elie, Sadik Sadik Abdel-Maseeh, Elsaed Mohammad Awad
Department of Anesthesia, Intensive Care and Pain Medicine, Faculty of Medicine, Minia University, Minia, Egypt.
Department of Rheumatology, Rehabilitation and Physical Medicine, Faculty of Medicine, Assuit University, Assuit, Egypt.
Anesth Pain Med (Seoul). 2025 Apr;20(2):151-159. doi: 10.17085/apm.24125. Epub 2025 Jan 2.
Epidural steroid injections are frequently used to treat chronic radicular pain of a discogenic origin; however, their efficacy remains limited. Magnesium sulfate and dexmedetomidine are emerging adjuvants with the potential to enhance the effectiveness and prolong the therapeutic duration of steroid injections.
In this randomized, double-blind study, 90 patients with unilateral lower limb radiculopathy due to lumbar disc prolapse who did not respond to conservative treatment for 12 weeks were assigned to three groups. The control group received dexamethasone (4 mg), lidocaine 2% (40 mg), and saline. The magnesium group received magnesium sulfate (200 mg) with dexamethasone and lidocaine. The dexmedetomidine group received dexmedetomidine (50 mg), dexamethasone, lidocaine, and saline. Pain intensity was assessed using the visual analog scale at 1 week and 1, 3, and 6 months post-treatment. Secondary outcomes included the Modified Oswestry Disability Index (MODI), analgesic consumption, and procedure-related complications.
Both magnesium and dexmedetomidine significantly reduced pain, disability, and analgesic consumption for up to 3 months. By 6 months, the magnesium group demonstrated significant improvement in pain scores and MODI and a decline in ibuprofen use compared to the control and dexmedetomidine groups.
Magnesium significantly reduced pain intensity, disability, and analgesic consumption over a 6-month observation period.
硬膜外类固醇注射常用于治疗椎间盘源性慢性神经根性疼痛;然而,其疗效仍然有限。硫酸镁和右美托咪定是新兴的辅助药物,有可能提高类固醇注射的有效性并延长治疗持续时间。
在这项随机、双盲研究中,将90例因腰椎间盘突出导致单侧下肢神经根病且对保守治疗12周无反应的患者分为三组。对照组接受地塞米松(4毫克)、2%利多卡因(40毫克)和生理盐水。硫酸镁组接受硫酸镁(200毫克)加地塞米松和利多卡因。右美托咪定组接受右美托咪定(50毫克)、地塞米松、利多卡因和生理盐水。在治疗后1周以及1、3和6个月时,使用视觉模拟量表评估疼痛强度。次要结局包括改良奥斯维斯特里功能障碍指数(MODI)、镇痛药消耗量和与操作相关的并发症。
硫酸镁和右美托咪定在长达3个月的时间内均显著减轻了疼痛、功能障碍和镇痛药消耗量。到6个月时,与对照组和右美托咪定组相比,硫酸镁组在疼痛评分和MODI方面有显著改善,布洛芬使用量有所下降。
在6个月的观察期内,硫酸镁显著降低了疼痛强度、功能障碍和镇痛药消耗量。